Endometriosis - High Unmet Need Continues to Challenge the Pipeline Drugs

Wednesday, February 10, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016 This is an essential source of information and analysis on the global endometriosis market. The report identifies the key trends shaping and driving the dynamism in the global endometriosis
market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly the report provides valuable insight
on the pipeline products within the global endometriosis market. ( http://www.bharatbook.com/detail.asp?id=132169&rt=Endometriosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html ) Endometriosis Market is Forecast to Show Low Growth till 2016 It estimates that the global endometriosis market was valued at $1.7 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.3 billion by 2016. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market is weak due to the lack of diagnostic techniques disease awareness and poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by moderately satisfied patients with attractively-priced efficacious branded off-labels and generic products. High Unmet Need Continues to Challenge the Pipeline Drugs It has found that the endometriosis market has huge unmet needs and patients still show a moderate response to the currently prescribed generics and off-label drugs. The current healthcare market is unable to cater to the need of patients suffering from endometriosis. The market is wide open for novel entrants to show progress in the current treatment paradigm. The treatments used are generics and off-label medications from four major therapy classes which include Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) birth control pills gonadotropin - releasing hormone (GnRH) agonists and progestins. The drugs available for endometriosis patients are the lowest on efficacy profiles which can either worsen the condition or cause serious adverse effects. Overall the endometriosis market is expected to be a relatively open market until 2016 with huge opportunities for value capture. Major Companies Focus on the Endometriosis Drug Development Landscape It predicts that Bayer AG Pfizer Inc. AEterna Zentaris Inc Neurocrine Biosciences Inc and KV Pharmaceuticals Company will become the leading competitors in the global endometriosis market. The current competitive landscape comprises of only generics and off-label therapies none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure. The above named five companies with some of the most technologically advanced products in their pipeline portfolio are expected to attract the most investor attention in the coming years. Any company that successfully targets disease modification will become a major player in the endometriosis market. Weak Pipeline Candidates Raise no Hopes for Endometriosis Treatment Paradigm It analysis shows that products for endometriosis in the developmental pipeline are weak with 29 molecules in various phases of clinical development including 10 first-in-class molecules none of which are likely to enter the market before 2016. These first-in-class molecules have a distinct advantage over the currently marketed products for endometriosis in terms of better symptomatic management but not with respect to disease cure. These molecules don’t display any improvements in safety adverse event and efficacy profiles displaying poor pipeline activity. The pipeline includes GnRH receptor antagonists estrogens progesterone receptor modulators phosphodiesterase inhibitors nerve growth factor (NGF)-neutralizing monoclonal antibodies and aromatase inhibitors for the treatment of endometriosis. To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132169&rt=Endometriosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store